UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements

·         Total resolution of HS inflammatory lesions, including draining tunnels, for 40.1% of people at three years (IHS4-100): Additionally, 59.1% and 77.4% achieved IHS4‑90 and IHS4-75, respectively*

·         High rates of improvement from moderate or severe HS to mild disease: 59.4% of people achieved at least mild HS at three years, as assessed by IHS4*

• Substantial reduction in HS disease severity: The proportion of people with severe HS, assessed by IHS4, fell from 87.4% at baseline to 14.7% at three years*

Brussels (Belgium), February 4, 2026 – 07:00 (CEST) – UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials^ for BIMZELX^®▼ (bimekizumab) in moderate to severe HS. Bimekizumab, the first and only medicine approved to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL‑17F),¹ demonstrated total resolution of inflammatory lesions and substantial improvements in disease severity, sustained to three years.^2,3,4,5 This data will be presented at the 15^th Conference of the European Hidradenitis Suppurativa Foundation (EHSF).

“The inflammatory lesions seen in HS, particularly draining tunnels, can be devastating for people living with this disease – not only because of the pain and profound impact on daily life, but also due to the long-term structural damage and scarring they often cause,” said Professor Thrasyvoulos Tzellos, Head Physician, Department of Dermatology, Nordland Hospital Trust, Bodø, Norway. “These data show that bimekizumab delivers high long-term resolution rates of these lesions, underscoring its sustained control of inflammation and potential to avoid structural damage and disease progression.”

“The data at EHSF showed bimekizumab’s ability to reduce HS disease severity over an extended three-year period. The depth and durability of efficacy reinforces its importance for both people living with HS and the clinical community,” said Donatello Crocetta, Chief Medical Officer, UCB. “We are proud to begin 2026 with more robust long-term clinical evidence that reflects UCB’s commitment to delivering unique treatment options, and we look forward to sharing additional bimekizumab data at AAD later this quarter.”

UCB will present four abstracts on bimekizumab in HS at the 15^th Conference of the European Hidradenitis Suppurativa Foundation (EHSF), 4–6 February 2026, in San Giljan, Malta. These data underscore UCB’s leadership in providing rigorous clinical research and ensuring its solutions have a real, lasting impact for people living with severe chronic inflammatory diseases.

Of people with HS at baseline, 40.1% (147/367) of those assessed at three years achieved IHS4‑100.²* In addition, 59.1% (217/367) and 77.4% (284/367) of those assessed at three years achieved IHS4‑90 and IHS4-75, respectively.²* In a second analysis, the proportion of people with severe HS, as assessed by IHS4, fell from 87.4% (486/556) at baseline to 14.7% (54/367) at three years.³* Further, the proportion of people with mild or inactive HS, as assessed by IHS4, rose from 0.0% (0/556) at baseline to 59.4% (218/367) at three years.³* This analysis also showed the mean (standard deviation given in brackets) draining tunnel count was 3.8 (4.3) at baseline and decreased to 0.9 (2.0) at year three.³* A separate analysis demonstrated meaningful improvements in a key health-related quality-of-life outcome sustained to three years.⁵*

*OC: Data are reported as observed case (OC). The data reported are from an observational, open‑label study. Patients completing the 48-week BE HEARD I & II studies could enroll in BE HEARD EXT and receive open-label bimekizumab (BKZ) 320 mg every 2 weeks (Q2W) or Q4W based on HiSCR90 response averaged from Weeks 36, 40 and 44.⁶ Data are reported for patients randomized to BKZ from baseline in BE HEARD I & II who entered BE HEARD EXT (BKZ Total group, n=556) at Week 48. Only patients who entered the third year are included.^2,3,4,5 The approved dosing regimen is bimekizumab 320 mg Q2W to Week 16 and then 320 mg Q4W thereafter.¹ Results included patients receiving both Q2W and Q4W after Week 48. All patients who continued in the trial after Week 48 were subsequently switched to Q4W by the end of year three.